Geneva Capital Management LLC Has $8.79 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Geneva Capital Management LLC reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 112,977 shares of the medical device company’s stock after selling 17,691 shares during the period. Geneva Capital Management LLC’s holdings in DexCom were worth $8,786,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in shares of DexCom by 2.2% in the third quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after acquiring an additional 214,136 shares during the last quarter. Jennison Associates LLC increased its stake in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares during the last quarter. Groupama Asset Managment increased its stake in shares of DexCom by 1.1% in the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of DexCom by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after acquiring an additional 91,051 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,083 shares of company stock worth $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 0.6 %

NASDAQ DXCM opened at $81.96 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a 50-day simple moving average of $84.90 and a 200 day simple moving average of $76.94. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $32.03 billion, a PE ratio of 57.31, a PEG ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DXCM. Canaccord Genuity Group upped their price target on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.